Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3985863 · 1 trial · 1 indication
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3985863 | EXPERIMENTAL | Administered subcutaneously (SC) |
| Placebo | PLACEBO_COMPARATOR | Administered SC |
| Name | Type | Description |
|---|---|---|
| LY3985863 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Are native Chinese participants * Are overtly healthy * Have body weight of at least 50.0 kilogram (kg) for male or 45.0 kg for female and a body mass index of 20.0 to 30.0 kilogram per square meter (kg/m²), inclusive * Have a stable body weight within 3 months Exclusion Crit...
LY3985863 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, studied in healthy participants. A completed trial evaluated its safety and tolerability in 24 healthy volunteers in China.
LY3985863 is being studied for use in healthy participants, meaning it is not yet indicated for any specific disease. Its Phase 1 trial, NCT07030127, was designed to assess the drug in healthy volunteers, a common early step in clinical development.
LY3985863 is developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker LLY. The company is conducting clinical trials to evaluate this investigational small molecule.
LY3985863 is in Phase 1 clinical development. A Phase 1 trial, NCT07030127, has been completed, involving 24 healthy participants. The drug is investigational and has not been approved by regulatory authorities.
LY3985863 has one clinical trial, NCT07030127, titled "A Study of LY3985863 in Healthy Participants." This Phase 1, randomized, double-blind, placebo-controlled trial was completed in China, enrolling 24 healthy adults aged 18 years and older.
LY3985863 is not FDA approved. It is an investigational drug in Phase 1 clinical development. The completed trial, NCT07030127, was conducted in healthy participants to evaluate the drug's safety and tolerability, but it has not been approved for any medical use.